Retrieve Medical (RMHI) 10-Q 9 Feb 23 2023 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Dec. 31, 2022	Feb. 08, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2022
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--09-30
Entity File Number	005-87668
Entity Registrant Name	PEAK PHARMACEUTICALS, INC.
Entity Central Index Key	0001452804
Entity Tax Identification Number	26-1973257
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	14201 N. Hayden Road
Entity Address, Address Line Two	Suite A-1
Entity Address, City or Town	Scottsdale
Entity Address, State or Province	AZ
Entity Address, Postal Zip Code	85260
City Area Code	(480)
Local Phone Number	659-6404
Entity Current Reporting Status	No
Entity Interactive Data Current	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	true
Entity Common Stock, Shares Outstanding		78,363,567

CONSOLIDATED BALANCE SHEETS (Un

CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)	Dec. 31, 2022	Sep. 30, 2022
Current assets:
Cash	$ 96,720	$ 127,599
Prepaid expenses	5,760	2,750
Total Assets	102,480	130,349
Current liabilities
Accounts payable (including $199,693 and $153,681 due to related parties)	307,146	224,548
Accrued liabilities	125,730	123,955
Convertible notes payable	10,000	10,000
Notes payable	228,000	228,000
Notes payable - related party	35,000	35,000
Total Liabilities	705,876	621,503
Stockholders’ deficit
Preferred stock, $0.0001 par value, 25,000,000 authorized, none issued or outstanding
Common stock, $0.0001 par value, 300,000,000 shares authorized, 78,363,567 shares issued and outstanding	7,836	7,836
Additional paid in capital	4,855,566	4,855,566
Accumulated deficit	(5,466,798)	(5,354,556)
Total Stockholders’ Deficit	(603,396)	(491,154)
Total Liabilities and Stockholders’ Deficit	$ 102,480	$ 130,349

CONSOLIDATED BALANCE SHEETS (_2

CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($)	Dec. 31, 2022	Sep. 30, 2022
Statement of Financial Position [Abstract]
Accounts Payable, Related Parties, Current	$ 199,693	$ 153,681
Preferred Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Preferred Stock, Shares Authorized	25,000,000	25,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized	300,000,000	300,000,000
Common Stock, Shares, Issued	78,363,567	78,363,567
Common Stock, Shares, Outstanding	78,363,567	78,363,567

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Operating expenses:
General and administrative (including expenses to related party of $46,012 and $4,770)	$ 110,412	$ 52,063
Total operating expenses	110,412	52,063
Operating loss	(110,412)	(52,063)
Other (expense) income:
Interest expense (including related party interest of $882 and $132)	(1,830)	(8,831)
Gain on forgiveness of debt		1,539
Total other expenses, net	(1,830)	(7,292)
Net loss	$ (112,242)	$ (59,355)
Per share information:
Weighted average shares outstanding - basic and diluted	78,363,567	78,363,567
Net loss per share - basic and diluted	$ 0	$ 0

CONSOLIDATED STATEMENTS OF OP_2

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (Parenthetical) - USD ($)	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party	$ 46,012	$ 4,770
Interest Expense, Related Party	$ 882	$ 132

CONSOLIDATED STATEMENT OF STOCK

CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT (EQUITY) (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Sep. 30, 2021	$ 7,836	$ 4,855,566	$ (5,189,587)	$ (326,185)
Shares, Outstanding, Beginning Balance at Sep. 30, 2021	78,363,567
Net loss			(59,355)	(59,355)
Ending balance, value at Dec. 31, 2021	$ 7,836	4,855,566	(5,248,942)	(385,540)
Shares, Outstanding, Ending Balance at Dec. 31, 2021	78,363,567
Beginning balance, value at Sep. 30, 2022	$ 7,836	4,855,566	(5,354,556)	(491,154)
Shares, Outstanding, Beginning Balance at Sep. 30, 2022	78,363,567
Net loss			(112,242)	(112,242)
Ending balance, value at Dec. 31, 2022	$ 7,836	$ 4,855,566	$ (5,466,798)	$ (603,396)
Shares, Outstanding, Ending Balance at Dec. 31, 2022	78,363,567

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities:
Net loss	$ (112,242)	$ (59,355)
Adjustment to reconcile net loss to net cash used in operating activities:
Gain on debt forgiveness		(1,539)
Change in operating assets and liabilities:
Prepaid expenses	(3,010)	(5,500)
Accounts payable	36,586	(6,216)
Accounts payable - related parties	46,012	(9,090)
Accrued liabilities	1,775	38,102
Net cash used in operating activities	(30,879)	(43,598)
Cash flows used in financing activities:
Payments on notes payable		(20,000)
Payment on convertible note payable		(10,000)
Net cash flows used in financing activities:		(30,000)
Net change in cash	(30,879)	(73,598)
Cash, beginning of period	127,599	261,152
Cash, end of period	96,720	187,554
Supplemental disclosure of cash flow information
Cash paid for interest
Cash paid for income taxes

NATURE OF OPERATIONS, BASIS OF

NATURE OF OPERATIONS, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
NATURE OF OPERATIONS, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 1 – NATURE OF OPERATIONS, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The Company was incorporated in Nevada on December 18, 2007. After a number of name changes, we again, changed our name to Peak Pharmaceuticals, Inc. on December 23, 2014. This name was consistent with our business operations and plans relating to development, manufacturing and marketing of hemp-based nutraceutical and supplement products for the human and animal health markets. On October 1, 2015, we discontinued certain operations of the Company. The Company is currently a “shell company” (as such term is defined in Rule 12b-2 under the Exchange Act). Throughout this report, the terms “our,” “we,” “us,” and the “Company” refer to Peak Pharmaceuticals, Inc. and its wholly-owned subsidiary, Peak BioPharma Corp. Basis of Presentation The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles (“GAAP”) for interim financial statements, instructions to Form 10-Q, and Regulation S-X. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted. These unaudited condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in our annual report on Form 10-K for the year ended September 30, 2022. In management’s opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation to make our financial statements not misleading have been included. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year, or any other period. Basis of Consolidation The unaudited condensed consolidated financial statements include the financial statements of the Company and our wholly owned subsidiary Peak BioPharma Corp. All inter-company balances and transactions among the companies have been eliminated upon consolidation. Use of Estimates The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Significant estimates made in connection with the accompanying consolidated financial statements include the valuation allowances against net deferred tax assets and accounting for convertible debt. Loss Per Share We calculate net loss per share in accordance with ASC Topic 260, Earnings per Share As of December 31, 2022, the Company had one convertible note with principal and accrued interest totaling $18,067. The note holders are entitled, at their option, to convert all or a part of their principal and accrued interest at the date into shares of the of common stock in the Company at a price equal to a 20% discount to the closing price of the common stock on the date of the lender’s notice of conversion, subject to a floor of $0.01. These common stock equivalents of approximately 163,655 271,936 As of December 31, 2022 and September 30, 2022, the Company had 3,291,000 Recently Issued Accounting Pronouncements Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statements. From time to time, new accounting pronouncements are issued that we adopt as of the specified effective date. We believe that the impact of recently issued standards that are not yet effective may have an impact on our results of operations and financial position. On August 5, 2020, the FASB issued Accounting Standards Update (ASU) 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40 In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Recently Adopted Accounting Pronouncements There were no recently adopted accounting pronouncements had a material effect on the Company’s financial statements.

GOING CONCERN AND MANAGEMENT_S

GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS	3 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS	NOTE 2 – GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS As of December 31, 2022, the Company had an accumulated deficit of $ 5,466,798 603,396 112,242 30,879 96,720 Accordingly, the accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. GAAP, which contemplates continuation of the Company as a going concern and the realization of assets and the satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the unaudited condensed consolidated financial statements do not necessarily represent realizable or settlement values. The unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	3 Months Ended
	Dec. 31, 2022
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 3 – RELATED PARTY TRANSACTIONS Parties, which can be corporations or individuals, are considered to be related if they have the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Companies are also considered to be related if they are subject to common control or common significant influence. Accounts payable – related parties are amounts payable to current and former officers and directors for services provided to the Company totaling $ 199,693 153,681 124,816 78,804 46,012 4,770

CONVERTIBLE NOTES PAYABLE AND N

CONVERTIBLE NOTES PAYABLE AND NOTES PAYABLE	3 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
CONVERTIBLE NOTES PAYABLE AND NOTES PAYABLE	NOTE 4 – CONVERTIBLE NOTES PAYABLE AND NOTES PAYABLE Convertible Notes Payable Loan with Trius Holdings Limited On March 17, 2017, the Company entered into an agreement with Trius Holdings Limited (“Trius”). Pursuant to the terms of the agreement, Trius acquired a 12% convertible note with an aggregate face value of $ 10,000 8,067 7,689 Notes Payable Loan with Mediapark Investments Limited On January 10, 2018, the Company entered into an agreement with Mediapark Investments Limited (“Mediapark”.) Pursuant to the terms of the agreement, Mediapark acquired a 12% promissory note with an aggregate face value of $ 23,000 16,152 15,282 Loans with Officer On June 14, 2021, the Company entered into an agreement with our sole officer and director. Pursuant to the terms of the agreement, we received a promissory note in the amount of $ 5,000 541 415 On September 28, 2021, the Company entered into a note payable with our sole officer and director for $30,000. The note is unsecured, is due and payable in full on December 31, 2021 and accrues interest at a rate of 1.5% per annum. As of the December 31, 2022 and September 30, 2022, the total accrued interest owing under this note was $ 3,116 2,360 Other Notes Payable During the twelve months ended September 30, 2021, the Company entered into twelve notes payable totaling $ 240,000 25,911 23,250

OPTIONS

OPTIONS	3 Months Ended
	Dec. 31, 2022
Fair Value Disclosures [Abstract]
OPTIONS	NOTE 5 – OPTIONS No stock options were granted during the three months ended December 31, 2022 and 2021. The following is a summary of outstanding stock options issued to employees and directors as of December 31, 2022 and September 30, 2022: Schedule of share-based compensation, stock options, activity Number Exercise Price per Average Outstanding December 31, 2022 and September 30, 2022 2,916,000 $ 0.0067 1.20 Exercisable, December 31, 2022 and September 30, 2022 2,916,000 $ 0.0067 1.20 The following is a summary of outstanding stock options issued to non-employees, excluding directors, as of December 31, 2022 and September 30, 2022: Schedule of share-based compensation, stock options, activity Number Exercise Price per Average Outstanding December 31, 2022 and September 30, 2022 375,000 $ 0.0067 0.79 Exercisable, December 31, 2022 and September 30, 2022 375,000 $ 0.0067 0.79 There was no equity-based compensation for the three months ended December 31, 2022 and 2021.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Dec. 31, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 6 – SUBSEQUENT EVENTS On January 23, 2023, the Company executed a Settlement Agreement and Mutual Release with four parties for outstanding accounts payable, resulting in a gain on forgiveness of debt of approximately $45,490, including $24,340 from related parties.

NATURE OF OPERATIONS, BASIS O_2

NATURE OF OPERATIONS, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles (“GAAP”) for interim financial statements, instructions to Form 10-Q, and Regulation S-X. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted. These unaudited condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in our annual report on Form 10-K for the year ended September 30, 2022. In management’s opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation to make our financial statements not misleading have been included. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year, or any other period.
Basis of Consolidation	Basis of Consolidation The unaudited condensed consolidated financial statements include the financial statements of the Company and our wholly owned subsidiary Peak BioPharma Corp. All inter-company balances and transactions among the companies have been eliminated upon consolidation.
Use of Estimates	Use of Estimates The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Significant estimates made in connection with the accompanying consolidated financial statements include the valuation allowances against net deferred tax assets and accounting for convertible debt.
Loss Per Share	Loss Per Share We calculate net loss per share in accordance with ASC Topic 260, Earnings per Share As of December 31, 2022, the Company had one convertible note with principal and accrued interest totaling $18,067. The note holders are entitled, at their option, to convert all or a part of their principal and accrued interest at the date into shares of the of common stock in the Company at a price equal to a 20% discount to the closing price of the common stock on the date of the lender’s notice of conversion, subject to a floor of $0.01. These common stock equivalents of approximately 163,655 271,936 As of December 31, 2022 and September 30, 2022, the Company had 3,291,000
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statements. From time to time, new accounting pronouncements are issued that we adopt as of the specified effective date. We believe that the impact of recently issued standards that are not yet effective may have an impact on our results of operations and financial position. On August 5, 2020, the FASB issued Accounting Standards Update (ASU) 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40 In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Recently Adopted Accounting Pronouncements There were no recently adopted accounting pronouncements had a material effect on the Company’s financial statements.

OPTIONS (Tables)

OPTIONS (Tables)	3 Months Ended
	Dec. 31, 2022
STOCK OPTIONS
STOCK OPTIONS (Details 2)	Number Exercise Price per Average Outstanding December 31, 2022 and September 30, 2022 375,000 $ 0.0067 0.79 Exercisable, December 31, 2022 and September 30, 2022 375,000 $ 0.0067 0.79
Employee
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Schedule of share-based compensation, stock options, activity	The following is a summary of outstanding stock options issued to employees and directors as of December 31, 2022 and September 30, 2022: Schedule of share-based compensation, stock options, activity
Non-Employee
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Schedule of share-based compensation, stock options, activity	The following is a summary of outstanding stock options issued to non-employees, excluding directors, as of December 31, 2022 and September 30, 2022: Schedule of share-based compensation, stock options, activity

NATURE OF OPERATIONS, BASIS O_3

NATURE OF OPERATIONS, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - shares	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Sep. 30, 2022
Accounting Policies [Abstract]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	163,655	271,936
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	3,291,000		3,291,000

GOING CONCERN AND MANAGEMENT__2

GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS (Details Narrative) - USD ($)	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Sep. 30, 2022	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Retained Earnings (Accumulated Deficit)	$ 5,466,798		$ 5,354,556
Working captial deficiency	603,396
Net Income (Loss) Attributable to Parent	112,242	$ 59,355
Net Cash Provided by (Used in) Operating Activities	30,879	43,598
Cash	$ 96,720	$ 187,554	$ 127,599	$ 261,152

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Sep. 30, 2022
Related Party Transaction [Line Items]
Accounts Payable, Related Parties, Current	$ 199,693		$ 153,681
Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party	46,012	$ 4,770
Entity Controller By Sole Officer And Director [Member]
Related Party Transaction [Line Items]
Accounts Payable, Related Parties, Current	$ 124,816		$ 78,804

CONVERTIBLE NOTES PAYABLE AND_2

CONVERTIBLE NOTES PAYABLE AND NOTES PAYABLE (Details Narrative) - USD ($)	Dec. 31, 2022	Sep. 30, 2022	Jun. 14, 2021	Jan. 10, 2018	Mar. 17, 2017
Short-Term Debt [Line Items]
Convertible Notes Payable, Current	$ 10,000	$ 10,000
Notes Payable, Current	228,000	228,000
Convertible Notes Payable 1 [Member]
Short-Term Debt [Line Items]
Convertible Notes Payable, Current					$ 10,000
Interest Payable	8,067	7,689
Notes Payable 1 [Member]
Short-Term Debt [Line Items]
Interest Payable	16,152	15,282
Notes Payable, Current				$ 23,000
Officer [Member]
Short-Term Debt [Line Items]
Interest Payable	541	415
Notes Payable, Current			$ 5,000
Officer [Member]
Short-Term Debt [Line Items]
Interest Payable	3,116	2,360
Twelve Notes Payable [Member]
Short-Term Debt [Line Items]
Interest Payable	$ 25,911	23,250
Notes Payable, Current		$ 240,000

STOCK OPTIONS (Details)

STOCK OPTIONS (Details) - $ / shares	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Sep. 30, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	3,291,000		3,291,000
Employee
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	2,916,000		2,916,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 0.0067		$ 0.0067
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	1 year 2 months 12 days	1 year 2 months 12 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number	2,916,000		2,916,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 0.0067		$ 0.0067
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	1 year 2 months 12 days	1 year 2 months 12 days

STOCK OPTIONS (Details 2)

STOCK OPTIONS (Details 2) - $ / shares	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Sep. 30, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	3,291,000		3,291,000
Non-Employee
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	375,000		375,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 0.0067		$ 0.0067
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	9 months 14 days	9 months 14 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number	375,000		375,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 0.0067		$ 0.0067
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	9 months 14 days	9 months 14 days